Ying Fan

2.5k total citations · 1 hit paper
120 papers, 1.7k citations indexed

About

Ying Fan is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ying Fan has authored 120 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 59 papers in Cancer Research and 47 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ying Fan's work include Cancer Treatment and Pharmacology (48 papers), HER2/EGFR in Cancer Research (46 papers) and Breast Cancer Treatment Studies (46 papers). Ying Fan is often cited by papers focused on Cancer Treatment and Pharmacology (48 papers), HER2/EGFR in Cancer Research (46 papers) and Breast Cancer Treatment Studies (46 papers). Ying Fan collaborates with scholars based in China, United States and Australia. Ying Fan's co-authors include Fei Ma, Binghe Xu, Pin Zhang, Jiayu Wang, Yang Luo, Ruigang Cai, Qiao Li, Peng Yuan, Shanshan Chen and Qing Li and has published in prestigious journals such as Nature Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ying Fan

112 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Peers

Ying Fan

ONCOL

PRM

RNMI

Ana C. Garrido-Castro United States

G. Deplanque France

Arlene Berman United States

Akihiko Shimomura Japan

Marie-Christine Étienne-Grimaldi France

Dana T. Aftab United States

Ricardo Costa United States

Lourdes Calvo Spain

Ernesto Wasserman United States

Qingyuan Zhang China

Ana C. Garrido-Castro United States

Ying Fan

1.4k ×1.3

ONCOL

474 ×0.7

649 ×1.2

502 ×1.0

PRM

144 ×0.7

RNMI

Citations per year, relative to Ying Fan Ying Fan (= 1×) peers Ana C. Garrido-Castro

Countries citing papers authored by Ying Fan

Since Specialization

Citations

This map shows the geographic impact of Ying Fan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Fan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Fan more than expected).

Fields of papers citing papers by Ying Fan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Fan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Fan. The network helps show where Ying Fan may publish in the future.

Co-authorship network of co-authors of Ying Fan

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Fan. A scholar is included among the top collaborators of Ying Fan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Fan. Ying Fan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yin, Yongmei, Ying Fan, Xiaojia Wang, et al.. (2025). Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nature Medicine. 31(6). 1969–1975. 16 indexed citations breakdown →

Lan, Bo, Jiayu Wang, Qiao Li, et al.. (2025). The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study. The Breast. 81. 104470–104470. 3 indexed citations

Fan, Ying, Qingyuan Zhang, Min Yan, et al.. (2025). Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study. Nature Communications. 16(1). 3–3. 3 indexed citations

Chen, Xi, Lei Ji, Min Xiao, et al.. (2024). Evolution and prognostic significance of HER-2 changes from primary to residual disease in patients with HER-2–negative breast cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology. 42(16_suppl). 583–583.

Song, Ge, Min Xiao, Xi Chen, et al.. (2024). Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy. Thoracic Cancer. 15(30). 2193–2205. 2 indexed citations

Chen, Xi, Xiaoyan Qian, Min Xiao, et al.. (2024). Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy. The Breast. 78. 103792–103792. 1 indexed citations

Wang, Jiayu, Fei Ma, Yang Luo, et al.. (2020). Platinum‐based chemotherapy in advanced triple‐negative breast cancer: A multicenter real‐world study in China. International Journal of Cancer. 147(12). 3490–3499. 9 indexed citations

Li, Qiao, Xiuwen Guan, Shanshan Chen, et al.. (2019). Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. Clinical Cancer Research. 25(17). 5212–5220. 61 indexed citations

Lan, Bo, Fei Ma, Xiaoyu Zhai, et al.. (2018). The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. International Journal of Cancer. 143(1). 184–189. 27 indexed citations

10.

Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. Clinical Breast Cancer. 19(2). e370–e375. 5 indexed citations

11.

Zhu, Wenjie, Mei Liu, Ying Fan, et al.. (2018). Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. Cancer Medicine. 7(9). 4420–4433. 34 indexed citations

12.

Lan, Bo, Fei Ma, Shanshan Chen, et al.. (2018). Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. International Journal of Cancer. 143(10). 2499–2504. 16 indexed citations

13.

Zhang, Tongtong, Qing Li, Shanshan Chen, et al.. (2016). Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget. 8(22). 36750–36760. 5 indexed citations

14.

Yuan, Peng, Zhixun Zhao, Zihao Yang, et al.. (2016). A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment. Scientific Reports. 6(1). 33825–33825. 27 indexed citations

15.

Du, Feng, Peng Yuan, Jiayu Wang, et al.. (2015). Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China. Asian Pacific Journal of Cancer Prevention. 16(3). 903–907. 2 indexed citations

16.

Zhang, Tongtong, Qing Li, Binghe Xu, et al.. (2014). [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].. PubMed. 36(9). 697–702. 2 indexed citations

17.

Li, Qian, Binghe Xu, Pin Zhang, et al.. (2013). [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].. PubMed. 35(3). 207–11. 1 indexed citations

18.

Wang, Jiayu, Binghe Xu, Peng Yuan, et al.. (2012). TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy. Breast Cancer Research and Treatment. 135(2). 531–537. 40 indexed citations

19.

Yuan, Peng, Binghe Xu, Jiayu Wang, et al.. (2012). [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].. PubMed. 34(6). 465–8. 3 indexed citations

20.

Fan, Ying, et al.. (2010). A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients. The Breast. 19(5). 365–369. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact